Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

26.97
-0.4400-1.61%
Pre-market: 27.200.2300+0.85%07:34 EDT
Volume:66.81M
Turnover:1.81B
Market Cap:153.34B
PE:19.83
High:27.55
Open:27.41
Low:26.80
Close:27.41
52wk High:27.94
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:1.53
T/O Rate:1.18%
Dividend:1.72
Dividend Rate:6.38%
EPS(TTM):1.36
EPS(LYR):1.36
ROE:8.89%
ROA:5.68%
PB:1.77
PE(LYR):19.77

Loading ...

Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial

TIPRANKS
·
46 mins ago

BRIEF-Pfizer Says LB6V Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified At Time Of Analysis

Reuters
·
51 mins ago

Pfizer: Lb6v Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified at Time of Analysis

THOMSON REUTERS
·
51 mins ago

Pfizer: Planning Submissions for Lb6v Vaccine Candidate to Regulatory Authorities

THOMSON REUTERS
·
51 mins ago

Pfizer: Co & Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor Trial

THOMSON REUTERS
·
51 mins ago

Pfizer: Vaccine Candidate Lb6v Showed More Than 70% Efficacy in Preventing Lyme Disease in People Aged Five Years & Above

THOMSON REUTERS
·
51 mins ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Reuters
·
51 mins ago

Novo Nordisk’s GLP-1 Leadership Tested By FDA Warnings And Rising Rivals

Simply Wall St.
·
Yesterday

Pfizer (PFE) Balances Trial Setback With Quiet Pipeline Push

TIPRANKS
·
Mar 21

Pfizer Recommends Shareholders Reject Tutanota Mini-Tender Offer

MT Newswires Live
·
Mar 21

Pfizer Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 21

NYSE Most Active Issues

Dow Jones
·
Mar 20

Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer’s Oncology Story And Investment Case (PFE)?

Simply Wall St.
·
Mar 20

BRIEF-Talzenna Plus Xtandi Significantly Improves Radiographic Progression-Free Survival In Metastatic Prostate Cancer

Reuters
·
Mar 19

Pfizer Reports Positive Results in Prostate Cancer Study

Dow Jones
·
Mar 19

Pfizer Phase 3 TALAPRO-3 trial links TALZENNA plus XTANDI to improved rPFS in HRR-mutated mCSPC

Reuters
·
Mar 19

Pfizer - Results to Be Discussed With Global Health Authorities for Talzenna Indication Expansion

THOMSON REUTERS
·
Mar 19

Pfizer: Safety of Talzenna Plus Xtandi Was Consistent With Known Safety Profile of Each Medicine, and No New Safety Signals Were Identified

THOMSON REUTERS
·
Mar 19

Pfizer - Interim Analysis Shows Strong Trend Toward Improved Overall Survival

THOMSON REUTERS
·
Mar 19

Pfizer - Talzenna Plus Xtandi Meets Primary Endpoint With Significant Improvement in Rpfs

THOMSON REUTERS
·
Mar 19